Federated Hermes
IMDX

Federated Hermes’s Insight Molecular Diagnostics IMDX Stock Holding History

Federated Hermes’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-179
Closed -$1.15K – 2220
2022
Q4 		$1.15K Buy
179
+58
+48% +$639 ﹤0.01% 2048
2022
Q3 		$2K Buy
+121
New +$2.1K ﹤0.01% 1975
2020
Q2 		– Sell
-23
Closed -$1K – 2337
2020
Q1 		$1K Sell
23
-1,778
-99% -$87.2K ﹤0.01% 2137
2019
Q4 		$81K Buy
+1,801
New +$65K ﹤0.01% 1699

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Federated Hermes's IMDX Position: Q1 2023 in Review

Federated Hermes sold out of Insight Molecular Diagnostics (IMDX) in Q1 2023, closing a stake of 179 shares — an estimated $1.15K sold.

Federated Hermes first reported a position in IMDX in Q4 2019 and held it in 4 quarters. The position peaked at $81K in Q4 2019. 52 funds tracked by Wall St. Rank hold IMDX as of Q1 2023.

  • Federated Hermes reported no remaining Insight Molecular Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 179 Insight Molecular Diagnostics shares in Q1 2023, an estimated $1.15K.
  • Federated Hermes first reported a position in Insight Molecular Diagnostics in Q4 2019 and held it in 4 quarters.
  • Federated Hermes's Insight Molecular Diagnostics position peaked at $81K in Q4 2019.
  • 52 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.